{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"341","upperLimit":"1830","value":"569"},{"groupId":"OG001","lowerLimit":"502","upperLimit":"912","value":"710"},{"groupId":"OG002","lowerLimit":"602","upperLimit":"1100","value":"878.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Cmax for lorlatinib in patients in cohort A2","dispersionType":"Full Range","groups":[{"description":"Lorlatinib will be given at 100 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG000","title":"Cohort A2 DL 3A"},{"description":"Lorlatinib will be given at 150 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG001","title":"Cohort A2 DL4A"},{"description":"Lorlatinib will be given at 150 mg orally once daily continuously for 28 days. Patients must be 18 years of age or older at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG002","title":"Cohort A2 DL4A Expansion"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Day 15","title":"Pharmacokinetics A2-Cmax","type":"SECONDARY","unitOfMeasure":"ng/mL"}